Retinalyze, LLC Begins Enrolling Ophthalmology Practices

Retinalize, LLC is pleased to announce that it has signed contracts with several large multi-physician Ophthalmology groups in Florida to begin using the Retinalytics SVM analysis technology to assist physicians in the diagnosis of macular degeneration. Retinalize, LLC is a 50%/50% joint venture between Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, and Doctors Optimal Formula LLC , a physician exclusive anti-aging, health and wellness company.

Age-related Macular Degeneration (AMD) is the leading cause of blindness in US adults 55 years and older and is a progressive eye disease affecting more than 15 million Americans, with over 200,000 new cases diagnosed each year.

These new ophthalmology physician contracts are in addition to the recently signed exclusive agreement with the 5500 member National EYEPA Coalition which is exclusive to optometrists.

“It’s incredibly exciting to see the positive responses we have seen since recently launching the Retinalytics SVM analysis technology,” states Howard Loff, M.D., CEO of Retinalyze, LLC. “In addition to having signed up the National EYEPA Coalition, we have now been fortunate to also sign up some of the largest Ophthalmology practices in Florida. We expect this trend to continue throughout the United States as well as internationally. As a result of the positive feedback that we are receiving from both optometrists and ophthalmologists alike, we hope Retinalytics SVM analysis technology will become the new standard of care in assisting doctors in their examination of ophthalmic diseases.”

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, added, “We are extremely pleased to see the rapid growth in the number of both optometrists and ophthalmologists signing up to use the Retinalytics SVM analysis technology for macular degeneration. I expect as the additional modules for diabetic retinopathy, hypertensive retinopathy and glaucoma are released, the revenue generated by our current and future optometry and ophthalmology customers will be significantly increased.”